Searles B, Nasrallah F, Darling E, Yarcusko S. How does the age of a blood sample affect its activated clotting time? Comparison of eight different devices. J Extra Corpor Technol 2002;34:175 7. 27. Welsby IJ, McDonnell E, El-Moalem H, Stafford-Smith M, Toffaletti JG. Activated clotting time systems vary in pre- cision and bias and are not interchangeable when following heparin management protocols during cardiopulmonary bypass. J Clin Monit Comput 2002;17:287 92. 28. Raymond PD, Ray MJ, Callen SN, Marsh NA. Heparin monitoring during cardiac surgery. Part 2: calculating the overestimation of heparin by the activated clotting time. Perfusion 2003;18:277 81. 29. Patteril M, Stafford-Smith M, Toffaletti JG, Bute BP, Milano CA, Welsby IJ. Changing systems for measuring activated clotting times: impact on the clinical practice of heparin anticoagulation during cardiac surgery. Clin Chim Acta 2005;356:218 24. 30. Chavez JJ, Foley DE, Snider CC, et al. A novel thrombe- lastograph tissue factor/kaolin assay of activated clotting times for monitoring heparin anticoagulation during car- diopulmonary bypass. Anesth Analg 2004;99:1290 4. 31. Ganter MT, Monn A, Tavakoli R, et al. Monitoring activated clotting time for combined heparin and aprotinin applica- tion: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot. Eur J Cardiothorac Surg 2006;30:278 84. 32. Ganter MT, Monn A, Tavakoli R, Klaghofer R, Zollinger A, Hofer CK. Kaolin-based activated coagulation time measured by Sonoclot in patients undergoing cardiopul- monary bypass. J Cardiothorac Vasc Anesth 2007;21:524 8. 33. Watson H, Davidson S, Keeling D, Haemostasis and Thrombosis Task Force of the British Committee for Stan- dards in Haematology. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: sec- ond edition. Br J Haematol 2012;159:528 40. 34. Prechel MM, Walenga JM. Emphasis on the role of PF4 in the incidence, pathophysiology and treatment of heparin induced thrombocytopenia. Thromb J 2013;11:7. 35. 